Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00349-1/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=lancetcovid22&utm_medium=email&_hsmi=283901121&_hsenc=p2ANqtz-9n_kfYpTb_N-62CqT-zXjeTMlL92xasA46feEHWIDDQv92MATNA-Ga9EM6a_w3R4Hp85_8nkvG01JZFtYSwuJMIYI-DA&utm_content=283899141&utm_source=hs_email